"Antigens, CD20" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Unglycosylated phosphoproteins expressed only on B-cells. They are regulators of transmembrane Ca2+ conductance and thought to play a role in B-cell activation and proliferation.
| Descriptor ID |
D018951
|
| MeSH Number(s) |
D23.050.301.264.035.120 D23.050.301.264.051.120 D23.101.100.110.120 D23.101.100.150.120
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antigens, CD20".
- Chemicals and Drugs [D]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Surface [D23.050.301]
- Antigens, Differentiation [D23.050.301.264]
- Antigens, CD [D23.050.301.264.035]
- Antigens, CD20 [D23.050.301.264.035.120]
- Antigens, Differentiation, B-Lymphocyte [D23.050.301.264.051]
- Antigens, CD20 [D23.050.301.264.051.120]
- Biomarkers [D23.101]
- Antigens, Differentiation [D23.101.100]
- Antigens, CD [D23.101.100.110]
- Antigens, CD20 [D23.101.100.110.120]
- Antigens, Differentiation, B-Lymphocyte [D23.101.100.150]
- Antigens, CD20 [D23.101.100.150.120]
Below are MeSH descriptors whose meaning is more specific than "Antigens, CD20".
This graph shows the total number of publications written about "Antigens, CD20" by people in this website by year, and whether "Antigens, CD20" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2009 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2016 | 0 | 2 | 2 |
| 2017 | 2 | 7 | 9 |
| 2018 | 4 | 1 | 5 |
| 2019 | 1 | 1 | 2 |
| 2020 | 2 | 0 | 2 |
| 2021 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Antigens, CD20" by people in Profiles.
-
It is time to adapt anti-CD20 administration schedules to allow efficient anti-SARS-CoV-2 vaccination in patients with lymphoid malignancies. Haematologica. 2022 03 01; 107(3):572-573.
-
Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy. Am J Hematol. 2021 08 01; 96(8):934-944.
-
Prolonged and severe SARS-CoV-2 infection in patients under B-cell-depleting drug successfully treated: A tailored approach. Int J Infect Dis. 2021 Jun; 107:247-250.
-
Immunohistochemistry patterns of SARS-CoV-2 deaths in forensic autopsies. Leg Med (Tokyo). 2021 Jul; 51:101894.
-
Reactivation of SARS-CoV-2 after Rituximab in a Patient with Multiple Sclerosis. Mult Scler Relat Disord. 2021 Jul; 52:102922.
-
Protracted SARS-CoV-2 pneumonia with rituximab treatment: About two cases. J Med Virol. 2021 Jul; 93(7):4141-4144.
-
Beyond COVID-19: DO MS/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies? Mult Scler Relat Disord. 2020 Nov; 46:102482.
-
COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases. Clin Exp Immunol. 2020 11; 202(2):149-161.
-
Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine? Eur J Cancer. 2020 09; 136:4-6.
-
COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies. Mult Scler Relat Disord. 2020 Sep; 44:102306.